New Breakthrough in Alzheimer's Diagnosis:
GE Healthcare's Brain Imaging Tool Gets
FDA Green Light

GE HealthCare has received FDA clearance for a new imaging tool designed to assist in the assessment of potential Alzheimer’s disease patients. The approval allows the use of Centiloid scaling for PET-based amyloid imaging analysis, integrated with the MIMneuro platform—a vendor-neutral solution. This innovative tool enables clinicians to more accurately measure amyloid plaque density in the brain, a crucial factor in diagnosing Alzheimer’s.

“Alzheimer’s is a complex and challenging disease for patients, caregivers, and healthcare systems alike,” said Andrew Nelson, CEO of MIM Software at GE HealthCare. “With the introduction of Centiloid scaling in MIMneuro, we provide a standardized metric that helps healthcare providers estimate amyloid plaque density with greater confidence, aiming to enhance patient access to advanced, personalized care.”

This development coincides with the release of new Alzheimer’s treatments, including Eli Lilly’s Kisunla and Eisai and Biogen’s Lequembi, highlighting the growing need for precise diagnostic tools in the fight against this debilitating disease.